Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it's a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy.
The Accuray Stellar solution, a configuration of the Radixact® Treatment Delivery System, will be featured at Accuray booth #525 during the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California, September 28 to 30. Meeting attendees are invited to attend the U.S. unveiling at the company's booth on Sunday, September 28, at 11:30 am PT.
Said CEO Suzanne Winter, "Innovations in radiation medicine, such as adaptive radiotherapy, are enabling clinicians to deliver more precise treatments that can lead to better tumor control and potentially higher survival rates. Our goal with Accuray Stellar is to provide tools that make it simple, fast and practical for medical teams to adopt adaptive radiotherapy techniques where needed, regardless of the stage of the patient's cancer journey.”
ARAY shares nicked up three cents, or 1.8%, to $1.70.
